Accession Number:

AD1064664

Title:

A Vaccine to Prevent Leishmaniasis

Descriptive Note:

Technical Report,15 Sep 2017,14 Sep 2018

Corporate Author:

BAYLOR COLL OF MEDICINE HOUSTON TX HOUSTON United States

Personal Author(s):

• Hotez ,Peter J.

Report Date:

2018-10-01

Pagination or Media Count:

33.0

Abstract:

Building on extensive preliminary data and an established consortium of academic, government, military, and product development partners, we propose to develop a production process for a novel, bivalent vaccine against leishmaniasis, a serious neglected tropical disease NTD of military and civilian personnel now spreading rapidly in conflict zones of the Middle East and Central Asia. The proposed Cutaneous Leishmania Vaccine CL-Vax is a bivalent, recombinant protein-based vaccine that will be comprised of a specific Leishmania parasite antigen together with a novel sand fly salivary antigen, co-administered at bedside with an adequate adjuvant. The components of the vaccine will be extensively characterized, and their immunogenicity and efficacy will be confirmed in animal models.

Descriptors:

• biological sciences
• systems biology
• biology
• tropical diseases
• infectious diseases
• vaccines

Subject Categories:

• Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE